AstraZeneca PLC Dealing by Person Closely Associated (0244O)

TIDMAZN

RNS Number : 0244O

AstraZeneca PLC

01 November 2016

1 November 2016 15:30

Transaction by Person Closely Associated with a Person Discharging Managerial Responsibilities

Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation

On 31 October 2016, Mrs Susan Chipchase notified us that, on 27 October 2016, she purchased 100 AstraZeneca PLC Ordinary Shares of US$0.25 each at a price of GBP48.08 per share.

Mrs Chipchase is a person closely associated with Graham Chipchase, a Non-Executive Director of AstraZeneca PLC.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------- 
 a)   Name                       Susan Chipchase 
---  -------------------------  ------------------------------------ 
 2    Reason for the notification 
---  --------------------------------------------------------------- 
 a)   Position/status            Person Closely Associated 
                                  with a Person Discharging 
                                  Managerial Responsibilities 
                                  (PDMR) in respect of AstraZeneca 
                                  PLC 
---  -------------------------  ------------------------------------ 
 b)   Initial notification       Initial notification 
       /Amendment 
---  -------------------------  ------------------------------------ 
 3    Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  --------------------------------------------------------------- 
 a)   Name                       AstraZeneca PLC 
---  -------------------------  ------------------------------------ 
 b)   LEI                        Not applicable 
---  -------------------------  ------------------------------------ 
 4    Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  --------------------------------------------------------------- 
 a)   Description of             Ordinary Shares of US$0.25 
       the financial              each in AstraZeneca PLC 
       instrument, type 
       of instrument 
                                  GB0009895292 
       Identification 
       code 
---  -------------------------  ------------------------------------ 
 b)   Nature of the              Acquisition 
       transaction 
---  -------------------------  ------------------------------------ 
 c)   Price(s) and volume(s)       Price(s)         Volume(s) 
                                   ---------------  ---------- 
                                    4807.95 pence    100 
                                   ---------------  ---------- 
---  -------------------------  ------------------------------------ 
 d)   Aggregated information     Not applicable - single transaction 
 
 
       - Aggregated volume 
 
 
       - Price 
---  -------------------------  ------------------------------------ 
 e)   Date of the transaction    27 October 2016 
---  -------------------------  ------------------------------------ 
 f)   Place of the transaction   London 
---  -------------------------  ------------------------------------ 
 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Enquiries 
 Neil Burrows           UK/Global                                 [phone] 
 Vanessa Rhodes         UK/Global                                 [phone] 
 Karen Birmingham       UK/Global                                 [phone] 
 Rob Skelding           UK/Global                                 [phone] 
 Jacob Lund             Sweden                                    [phone] 
 Michele Meixell        US                                        [phone] 
 
 Investor Relations 
 Thomas Kudsk Larsen                                              [phone] 
 Craig Marks            Finance, Fixed Income, M&A                [phone] 
 Henry Wheeler          Oncology                                  [phone] 
 Mitchell Chan          Oncology                                  [phone] 
 Lindsey Trickett       Cardiovascular & Metabolic Diseases       [phone] 
 Nick Stone             Respiratory                               [phone] 
 Christer Gruvris       Autoimmunity, neuroscience & infection    [phone] 
 US toll free                                                     [phone] 
 

Adrian Kemp

Company Secretary, AstraZeneca PLC

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUAUSRNVAARAA

(END) Dow Jones Newswires

November 01, 2016 11:30 ET (15:30 GMT)